NASDAQ:PLXP

PLx Pharma (PLXP) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,000 shs
Average Volume
12.96 million shs
Market Capitalization
$603,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PLXP stock logo

About PLx Pharma Stock (NASDAQ:PLXP)

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

PLXP Stock News Headlines

Protalix Biotherapeutics Inc (PLX)
Vertex Pharmaceuticals Inc VRTX
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Vietnam National Petroleum Group (PLX)
PLx Pharma Inc (PLXPQ)
PLXPQ PLx Pharma Inc.
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
PLx Pharma Inc. Receives Nasdaq Delisting Notice
Short Volatility Alert: Plx Pharma Inc
PLx Pharma (PLXP) Q3 2022 Earnings Call Transcript
PLx Pharma down after Q3 revenue fell 94% Y/Y
Earnings Preview: PLx Pharma
PLXP Aug 2022 5.000 call
PLx Pharma downgraded at Oppenheimer after Q2 miss
PLx Pharma Q2 Loss Top Estimates, But Revenues Miss; Stock Down 15%
See More Headlines
Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
2002

Profitability

Net Income
$-46,130,000.00
Net Margins
-606.91%
Pretax Margin
-606.91%

Debt

Sales & Book Value

Annual Sales
$4.54 million
Book Value
$1.30 per share

Miscellaneous

Free Float
26,530,000
Market Cap
$603,000.00
Optionable
Not Optionable
Beta
3.79

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Natasha Giordano
    President, Chief Executive Officer & Director
  • Rita M. O'Connor
    CFO, Head-Manufacturing & Supply Chain
  • Mayme Lou Roettig
    Executive Medical Director
  • Thomas L. Long
    VP-Manufacturing & Technical Operations
  • Lawrence R. Perkins
    Chief Restructuring Officer

PLXP Stock Analysis - Frequently Asked Questions

How were PLx Pharma's earnings last quarter?

PLx Pharma Inc. (NASDAQ:PLXP) issued its quarterly earnings results on Friday, November, 12th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. The biotechnology company had revenue of $6.60 million for the quarter, compared to analyst estimates of $4.10 million. PLx Pharma had a negative net margin of 606.91% and a negative trailing twelve-month return on equity of 291.11%. The business's revenue for the quarter was up 560.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.40) earnings per share.

What other stocks do shareholders of PLx Pharma own?
When did PLx Pharma IPO?

PLx Pharma (PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

This page (NASDAQ:PLXP) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners